Celldex Therapeutics (NASDAQ:CLDX) traded at a new 52-week high today of $8.45. So far today approximately 694,000 shares have been exchanged, as compared to an average 30-day volume of 1.2 million shares.

Celldex Therapeutics Inc., a biopharmaceutical company, uses applications of immunology to prevent and treat diseases. The Company's products treat autoimmune diseases, cardiovascular diseases, cancer, and inflammation, as well as infectious diseases and organ transplant rejection.

Celldex Therapeutics (NASDAQ:CLDX) has potential upside of 38.4% based on a current price of $8.43 and analysts' consensus price target of $11.67. The stock should discover initial support at its 50-day moving average (MA) of $7.07 and subsequent support at its 200-day MA of $5.67.

In the past 52 weeks, shares of Celldex Therapeutics have traded between a low of $3.52 and a high of $8.45 and are now at $8.43, which is 139% above that low price. Over the past week, the 200-day moving average (MA) has gone up 1.3% while the 50-day MA has advanced 2.1%.

SmarTrend recommended that subscribers consider buying shares of Celldex Therapeutics on November 28th, 2012 as our proprietary SmarTrend analytics indicated a new Uptrend was in progress when shares hit $5.97. Since that recommendation, shares of Celldex Therapeutics have risen 37.3%. We continue to monitor CLDX for any potential shift so investors can protect gains and will alert SmarTrend subscribers immediately.